Checkpoint Inhibitor Therapy

A triple-therapy combination extended OS compared with historical data among certain patients with advanced HPV-positive cancers, according to one of the agent’s manufacturers.

Immune checkpoint inhibitor therapy appeared associated with an increased risk for major adverse cardiovascular events among patients with cancer and a prior history of cardiovascular disease, according to results of a retrospective study.

More thorough understanding of giant cell arteritis disease processes has shed light on how immune checkpoint inhibitors may be exacerbating this and other immune-mediated conditions, according to a presenter here.

Like so many rheumatology meetings over the last year and a half, the 2021 Congress of Clinical Rheumatology – East has adapted to suit the rolling waves of the pandemic.

Female patients with melanoma on immune checkpoint inhibitor therapy exhibited higher rates of dermatologic adverse events compared with male patients, according to a study presented at AAD VMX 2021.

Among patients with various malignancies, treatment with combination immune checkpoint inhibitor therapy was associated with increased incidence of cutaneous events compared with checkpoint monotherapy, according to a study.

Cutaneous immune-related adverse events are an early sign of immune-mediated toxic events, and dermatologists can play a role in screening for more severe events, according to a study.

Patients’ response to anti-CTLA-4 or anti-PD-1 checkpoint therapy for advanced melanoma, and their incidence of immune-related adverse events of grade 3 or higher, were similar regardless of preexisting autoimmune disease, according to data.

The use of immune checkpoint inhibitors in cancer care has expanded exponentially over the last few years.

Myositis due to immune checkpoint therapy is rare yet severe, with more than half of patients developing overlapping myasthenia gravis and/or myocarditis, leading to extended hospitalizations and respiratory failure, researchers noted.